ANEXT (China) key facts
as of Oct 2026- Developer of new drugs and delivery methods designed for anti-aging and reversing aging purposes.
- ANEXT (China) is valued at approximately $83.2M as of Oct 2026 (last reported valuation).
- It has raised $14.0M; the latest was Later Stage VC in Dec 2024.
- Notable investors include Huayi Capital, The Oriental Beauty Valley, Huilian Investment, Shanghai Huamin Investment.
- Status: Privately Held (backing).
ANEXT (China)'s last reported valuation, Aug 2024. Nothing priced has surfaced since.
- ·Watch ANEXT (China): the Monday email on marks, rounds and moves
ANEXT (China) funding rounds
No funding rounds for ANEXT (China) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs ANEXT (China)
4ANEXT (China) valuation
ANEXT (China)'s last reported valuation was $83.2 million in Aug 2024. No priced round, secondary trade or fund mark has surfaced since.
ANEXT (China) investors
4 investors are on record for ANEXT (China), including Huayi Capital, The Oriental Beauty Valley, Huilian Investment and Shanghai Huamin Investment.
About ANEXT (China)
Developer of new drugs and delivery methods designed for anti-aging and reversing aging purposes. The company can realize the development of new drugs and change the conventional drug delivery methods to obtain highly optimized cell therapy methods through the newly discovered "naturally domesticated" biomolecule drug carriers Exosomes and engineering transformation, providing customers with reliable and creative products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2013
- Employees
- 2
- Website
- anextcell.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.